The Cartalax Blend Research Matrix is an multi-target quad-peptide formulation combining Cartalax, BPC-157, TB-500, and KPV. Engineered to investigate multi-pathway extracellular remodeling and chondrogenic matrix stabilization, this complex pairs targeted chondrocyte gene regulation (Cartalax) with fibroblast signaling modulation (BPC-157), actin-mediated cellular migration (TB-500), and NF-κB-mediated cytokine downregulation (KPV).
Original price was: $149.00.$104.30Current price is: $104.30.
In stock
| Quantity | Discounted Price |
|---|---|
| 4 - 6 | $143.04 |
| 7 - 9 | $140.06 |
| 10 + | $137.08 |
The Cartalax Blend Research Matrix is a multi-pathway quad-peptide analytical standard combining four highly targeted bioactive peptides in a single formulation: Cartalax (20MG), BPC-157 (10MG), TB-500 (10MG), and KPV (10MG), delivering 50MG of total active peptide mass per unit.
This formulation is engineered to examine the interplay between epigenetic chondrocyte bioregulation, microvascular angiogenesis, cytoskeletal actin reorganization, and anti-inflammatory cytokine modulation:
Ala-Glu-Asp) that penetrates cell nuclei to modulate chondrocyte gene expression, stimulating synthesis of type II collagen and aggrecan while downregulating cartilage-degrading matrix metalloproteinases (MMPs).Lys-Pro-Val) that directly inhibits IκB degradation and blocks nuclear factor kappa B (NF-κB) nuclear translocation, attenuating pro-inflammatory cytokine surges (TNF-α, IL-1β, IL-6).Batch-verified for high analytical purity at Modern Aminos, the Cartalax Blend is supplied as a 50MG lyophilized dry solid in a 2R glass vial. Researchers study this matrix alongside complementary tissue remodeling and bioregulator standards available on the site, such as Wolverine Blend, GLOW Blend, KLOW Blend, and GHK-Cu.
| Component | Vial Mass | Peptide Sequence | Chemical Formula | Molecular Weight | Primary Target |
|---|---|---|---|---|---|
| Cartalax | 20MG | Ala-Glu-Asp |
C12H19N3O8 | 333.29 g/mol | Chondrocyte Nuclear DNA / ECM Synthesis |
| BPC-157 | 10MG | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
C62H98N16O22 | 1419.53 g/mol | VEGFR2 / FAK-Paxillin / Nitric Oxide |
| TB-500 | 10MG | Thymosin β4 Active Domain Sequence |
C212H350N56O78S | 4963.50 g/mol | G-Actin Sequestration / Cell Motility |
| KPV | 10MG | Lys-Pro-Val |
C16H32N4O5 | 384.48 g/mol | NF-κB Translocation / Cytokines |
The synergistic biochemical pathways and cellular targets of the Cartalax Blend Research Matrix in laboratory research include:
When evaluating published scientific literature for the individual constituents of the Cartalax Blend Research Matrix:
To evaluate peptide combinations, tissue specificity, and mechanistic targets, researchers compare the Cartalax Blend against alternative multi-peptide complexes available at Modern Aminos:
| Complex / Formulation | Active Research Materials | Primary Mechanistic Targets | Primary Research Focus |
|---|---|---|---|
| Cartalax Blend | Cartalax + BPC-157 + TB-500 + KPV | Chondrocyte DNA / Type II Collagen / VEGFR2 / G-Actin / NF-κB Blockade | Chondrogenic matrix stabilization, structural connective tissue modeling, chondrocyte bioregulation, and multi-pathway cytokine downregulation. |
| Wolverine Blend | BPC-157 + TB-500 | VEGFR2 Angiogenesis + G-Actin Cytoskeletal Motility | Baseline connective tissue modulation, microvascular endothelial tubulogenesis, and actin-mediated cellular migration. |
| GLOW Blend | GHK-Cu + BPC-157 + TB-500 | Copper Tripeptide ECM Remodeling + VEGFR2 + G-Actin | Fibroblast modulation, Type I/III collagen synthesis, epithelial barrier homeostasis, and extracellular matrix (ECM) remodeling. |
| KLOW Blend | GHK-Cu + BPC-157 + TB-500 + KPV | Copper ECM Synthesis + VEGFR2 + G-Actin + NF-κB Suppression | Comprehensive extracellular matrix (ECM) modulation combined with targeted pro-inflammatory cytokine attenuation. |
Yes, Modern Aminos is a highly trusted vendor for high-purity research chemicals and reference peptide complexes. Every batch undergoes strict third-party analytical testing (including HPLC and Mass Spectrometry) to verify minimum 98%+ chemical purity for each of the four peptide components, mass stoichiometry, correct molecular weights, and complete absence of synthesis impurities or cross-contamination.
The Cartalax Blend is a specialized multi-peptide analytical formulation containing 20MG Cartalax, 10MG BPC-157, 10MG TB-500, and 10MG KPV (50MG total mass) in a single lyophilized 2R glass vial, designed for simultaneous investigation of chondrogenic bioregulation, extracellular matrix (ECM) remodeling, endothelial tubulogenesis, and pro-inflammatory cytokine attenuation.
Cartalax functions as a short synthetic peptide bioregulator (Ala-Glu-Asp) that specifically targets chondrocyte gene expression. It upregulates the transcription of Type II collagen and aggrecan while downregulating matrix metalloproteinases (MMPs), effectively attenuating extracellular matrix degradation in chondrogenic models.
BPC-157 modulates endothelial tubulogenesis via VEGFR2 activation and supports localized fibroblast proliferation via FAK/paxillin signaling. Concurrently, TB-500 sequesters G-actin to drive rapid cellular motility and migration. Together, they facilitate synergistic structural matrix remodeling and microvascular network formation.
KPV (Lys-Pro-Val) acts as a targeted cytokine-modulating tripeptide by inhibiting IκB degradation and blocking NF-κB nuclear translocation. This effectively mitigates the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that would otherwise degrade structural components in challenged cellular models.
The Wolverine Blend (BPC/TB) is a dual blend for baseline standard for broad structural matrix modulation. The GLOW (GHK/BPC/TB) and KLOW (GHK/BPC/TB/KPV) blendmatrices incorporate GHK-Cu specifically for fibroblast modulation, epithelial barrier homeostasis, and Type I/III collagen remodeling. The Cartalax Blend Research Matrix replaces GHK-Cu to distinctly shift the biological focus away from superficial fibroblast modulation, directing research entirely toward chondrocyte bioregulation, structural matrix stabilization, and deep chondrogenic ECM restitution.
Modern Aminos utilizes gradient High-Performance Liquid Chromatography (HPLC) to resolve and quantify all four distinct peptide peaks to ensure >98% individual purity, coupled with Mass Spectrometry (MS) to verify the precise molecular mass of Cartalax (333.29 g/mol), BPC-157 (1419.53 g/mol), TB-500 (4963.50 g/mol), and KPV (384.48 g/mol).
Lyophilized Cartalax Blend Research Matrix 2R glass vials should be stored tightly sealed in a cool, dry environment (15°C to 25°C) or refrigerated for long-term preservation. Protect from direct light, heat exposure, and atmospheric moisture to maintain solid-state peptide stability.
Disclaimer: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research professional use only. They are not approved for human or animal use nor consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.
By purchasing this product, you confirm that:
Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.
If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.